Αποτελέσματα Αναζήτησης
Raloxifene (Evista®): An estrogen agonist/antagonist (or selective estrogen receptor modulator) approved by the FDA for prevention and treatment of osteoporosis. It lowers the risk of vertebral fracture by about 30% in patients with and about 55% in patients without prior vertebral fracture.
- Osteoporosis: A Review of Treatment Options - PMC - PubMed Central (PMC)
The AACE/ACE recommends denosumab as first-line therapy for...
- Osteoporosis: A Review of Treatment Options - PMC - PubMed Central (PMC)
This guideline summary addresses the assessment, diagnosis and current treatments for osteoporosis, including recommendations to prevent fragility fractures. It applies to postmenopausal women, and to men
The AACE/ACE recommends denosumab as first-line therapy for patients at high risk of fracture and for patients who are unable to use oral therapy. 3 Denosumab was the first biologic agent available for treatment of osteoporosis. It is a fully human monoclonal antibody that inhibits RANKL to decrease bone resorption.
Intravenous infusion in 100 mL in at least 15 min, requires eGFR >30–35 mL/min, ensure vitamin D-replete before infusion. Self-limited acute phase response (“flu-like illness”) in 30–40% of patients after first dose; too few reports of AFF and ONJ to estimate incidence.
18 Ιουλ 2023 · Osteoporosis requires long-term prevention or therapy based on specific bone medication and/or general measures; specific therapy principles encompass antiresorptive or osteoanabolic...
Adherence to osteoporosis therapies is essential to treatment efficacy, even with BPs, despite their long bone retention. Better adherence to BP therapy is associated with larger increases in BMD, and - when exceeding 75% - with lower rates of fracture.
26 Αυγ 2024 · Osteoporosis is caused by the cumulative effect of bone resorption in excess of bone formation. Bisphosphonates inhibit bone resorption with relatively few side effects. As a result, they are widely used to prevent osteoporotic fractures.
